Björn Petersson has taken over as CFO of Dicot
Press release: Uppsala, March 8, 2022. The experienced Björn Petersson has taken the role of CFO for the pharmaceutical company Dicot. Among the assignments that Björn worked on is the IPO of the investment company Flat Capital.
The pharmaceutical company Dicot has previously announced that it intends to broaden and strengthen the management for the next phase, where the focus will be on clinical studies, business development and partnerships with international pharmaceutical companies. In connection with CFO Jessica Roxhed announcing that she needed to reduce her working hours, Dicot chose to search for a new CFO.
Björn Petersson took office yesterday, Monday the 7th of March. Björn has extensive experience as CFO and other leading roles in business management from various industries, including several companies in the life science sector, such as Karessa, Cavidi and NeoDynamics. Since 2021, Björn has been involved in the investment company Flat Capital and its listing.
"Björn will, together with appointed new CEO Elin Trampe, form an important team to actively pursue business development, IR and financial management. Björn has a very broad and long experience and with his motivating leadership and holistic thinking, they will together be able to continue the work that Jessica and I hand over", says Göran Beijer, CEO of Dicot.
"I look forward to work together with the entire Dicot team to create optimal conditions to best drive the development of the drug candidate to "proof of concept" and a successful out-licensing to partners. The strong ambition in Dicot and the opportunities to be part of the next phase of business development make me feel great enthusiasm", says Björn Petersson, new CFO at Dicot.
For further information, please contact:
Göran Beijer CEO
Tel: +46 706 63 60 09
Email: [email protected]
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.
Om Dicot
Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.
Handelsinformation
IR-Kontakt
